

DAFTAR PUSTAKA

- Al Achkar, W., Moassass, F., Youssef, N., Wafa, A., 2016. Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients. *JBUON*, 21(2): pp 444 – 449.
- Albano, F., Zagaria, A., Anelli, L., Coccaro, N., Impera, L., Minervini, C. F., . . . Specchia, G., 2013. Gene expression profiling of chronic myeloid leukemia with variant t (9;22) reveals a different signature from cases with classic translocation. *Molecular Cancer*, 12: 36.
- Au, W. Y., Caguioa, P. B., Chuah, C., Hsu, S. C., Jootar, S., Kim, Dong-Wook., . . . Wang, Jianxiang., 2009. Chronic myeloid leukemia in Asia. *Int J Hematol*, 89: pp 14 – 23.
- Calabretta, B. dan Perrotti, D., 2004. The Biology of CML Blast Crisis. *Blood Journal*, DOI 10.1182/blood-2003-12-4111
- Chang J.S., Santhanam, R., Trotta, R., Neviani, P., Eiring, A. M., . . . Perrotti, D., 2007. High level of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2-dependent suppression on C/EBP α -driven myeloid differentiation. *Blood Journal*, 110(3): pp 994 – 1003.
- Chen, Q., Jin, Min., Zhu, Jianhua., Xiao, Qingzhong., dan Zhang, Li., 2013. Functions of heterogeneous nuclear ribonucleoproteins in stem cell potency and differentiation. *BioMed Research International*, <http://dx.doi.org/10.1155/2013/623978>
- Chu, Su., Li, Liang., Singh, Harjeet., dan Bhatia Ravi., 2007. BCR-Tyrosine 177 Plays an Essential Role in Ras and Akt Activation and in Human Hematopoietic Progenitor Transformation in Chronic Myelogenous Leukemia. *Cancer Research*, 67(14): pp 7045 – 7053.
- Cilloni, D. dan Sagilo, G., 2012. Molecular Pathways: BCR-ABL. *Clin Cancer Res*, 18(4): pp 930 – 937.
- Deb, P., Chakrabarti, P., Chakrabarty, S., Aich, R., Nath, U., Ray, S. S., Chaudhuri, U., 2014. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. *Indian Journal of Medical and Paediatric Oncology*, 35: pp 26 – 30.
- Deininger, M. W. N., Goldman, J. M., dan Melo, J. V., 2000. The molecular biology of chronic myeloid leukemia. *Blood Journal*, 96(10): pp 3343 – 3356.
- Di Bacco, A., Keeshan, K., McKenna, S. L., dan Cotter, T. G., 2005. Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis. *The Oncologist*, 5: pp 405 – 415.
- Eiring, A. M., Harb, J. G., Neviani, P., Garton, C., Oaks, J. J., Spizzo, R., . . . Perrotti, D., 2010. miR-328 Function as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts. *Cell*, 140(5): pp 652 - 665.

- Gaiger, A., Henn, T., Horth, E., Geissler, K., Mitterbauer, G., Maier-Dobersberger, T., . . . Lion, T., 1995. Increase of BCR-ABL Chimeric mRNA Expression in Tumor Cells of Patients With Chronic Myeloid Leukemia Precedes Disease Progression. *Blood Journal*, 86(6): pp 2371 – 2378.
- Geuens, T., Bouhy, D., dan Timmerman, V., 2016. The hnRNP family: insights into their role in health and disease. *Hum Genet*, 135: pp 851 – 867.
- Harb, J. G., Neviani, P., Oaks, J. J., Marcucci, G., Hokland, P., Roy, D., dan Perrotti, D., 2010. The BCR-ABL 1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML. *Blood Journals*, 116(21): 1222.
- Hehlmann, R., 2012. How I treat CML blast crisis. *Blood Journal*, 120(4): pp 737 – 747.
- Howlader, N., Noone, A. M., Krapcho, M., Miller, D., Bishop, K., Kosary, C. L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D. R., Chen, H. S., Feuer, E. J., Cronin, K. A. (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/. Diakses pada April 2017.
- Jamieson, C. H., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., . . . Weissman, I. L., 2004. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. *N Engl J Med*, 351(7): pp 657 – 667.
- Kang, Z. J., Liu, Y. F., Xu, L. Z., Long, Z. J., Huang, D., Yang, Y., . . . Liu, Q., 2016. The Philadelphia chromosome in leukemogenesis. *Chin J Cancer*, 35(48): pp 1 – 15.
- Khaled, S. A. A. dan Abd El Aziz, N. M. A., 2015. Demographic, clinical, and hematologic characteristics of patients with chronic myeloid leukemia in Upper Egypt: association with treatment responses. *The Egyptian Journal of Haematology*, 40(4): pp 195 – 200.
- Kumar, V., Abbas, A. K., dan Aster, J. C. 2013. *Robbins and Cotran Pathologic Basis of Disease*, 9th ed. Philadelphia: Elsevier Saunders.
- Lederer, A. O. dan Ostareck, D. H., 2004. Control of mRNA translation and stability in haematopoietic cells: The function of hnRNPs K and E1/E2. *Biology of the Cell*, 96: pp 407 – 411.
- Lee, J. P., Birnstein, E., Masiello, D., Yang, D., dan Yang, A. S., 2009. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. *Journal of Hematology & Oncology*, 2(30).
- Levine, P. H., Ajmera, K., O'Neill, B., Venkatesh, V., Garcia-Gonzales, P., dan Hoffman, H. J., 2016. Demographic factors related to young age at diagnosis of chronic myeloid leukemia in India. *Clinical Epidemiology and Global Health*, 4: pp 188 – 192.
- Lucas, C. M., Harris, R. J., Giannoudis, A., Davies, A., Knight, K., Watmough, S. J., . . . Clark, R. E., 2009. Chronic myeloid leukemia with the e13a2 BCR-ABL

- fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. *Hematologica*, 94(10): pp 1362 – 1367.
- Makeyev, A. V. dan Liebhaber, S. A., 2002. The poly(C)-binding protein: A multiplicity of functions and a search for mechanisms. *RNA*, 8: pp 265 – 278.
- Marega, M., Piazza, R. G., Pirola, A., Redaelli, S., Mogavero, A., Iacobucci, I., . . . Gambacorti-Passerini, C., 2010. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. *Leukemia*, 24: pp 1445 – 1449.
- Nowicki, M. O., Pawlowski, P., Fischer, T., Hess, G., Pawlowski, T., dan Skorski, T., 2003. Chronic myelogenous leukemia molecular signature. *Oncogene*, 22: pp 3952 – 3963.
- Perrotti, D. dan Calabretta, B., 2002. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. *Oncogene*, 21: pp 8577 – 8583.
- Perrotti, D., Cesi, V., Trotta, R., Guerzoni, C., Santilli, G., Campbell, K., . . . Calabretta, B., 2002. BCR-ABL suppresses CEBPalpha expression through inhibitory action of hnRNP E2. *Nature Genetics*, 30: pp 48 – 58.
- Perrotti, D., Jamieson, C., Goldman, J., dan Skorski, T., 2010. Chronic myeloid leukemia: mechanisms of blastic transformation. *The Journal of Clinical Investigation*, 120(7): pp 2254 – 2264.
- Polampalli, S., Choughule, A., Negi, N., Shinde, S., Baisane, C., Amre, P., . . . Parikh, P., 2008. Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. *Genetics and Molecular Research*, 7(4): pp 1138 – 1149.
- Quintas-Cardama, A. dan Cortes, J. E., 2006. Chronic Myeloid Leukemia: Diagnosis and Treatment. *Mayo Clin Proc*, 81(7): pp 973 – 988.
- Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., . . . Linsley, P. S., 2006. Gene expression changes associated with progression and response in chronic myeloid leukemia. *PNAS*, 103(8): pp 2794 – 2799.
- Rana, A., Shah, S. H., Rehman, N., Ali, S., Ali, G. M., Bhatti, S., dan Farooqi, A. A., 2011. Chronic myeloid leukemia: Attributes of break point cluster region-abelson (BCR-ABL). *Journal of Cancer Research and Experimental Oncology*, 3(6): pp 62 – 66.
- Reksodiputro, A. H., Tadjoeidin, H., Supandiman, I., Acang, N., Kar, A. S., Bakta, I Made., . . . Akbar, D. F., 2015. Epidemiology Study and Mutation Profile of Patients with Chronic Myeloid Leukemia (CML) in Indonesia. *J Blood Disord Transfus*, 6(3): pp 1 – 13.
- Rumpold, H. dan Webersinke, G., 2011. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia – is it all BCR-ABL? *Current Cancer Drug Targets*, 11: pp 3 – 19.

- Sarwar, S., Siddiqui, N., Zafar, W., Fasih, S., Basit, A., dan Hameed, A., 2015. Characteristics and outcomes of patients with chronic myelogenous leukemia in blast crisis. *J Ayub Med Coll Abbottabad*, 27(2): pp 371 – 374.
- Tauchi, T., Miyazawa, K., Feng, G. S., Broxmeyer, H. E., dan Toyama, K., 1997. A Coiled-coil Tetramerization Domain of BCR-ABL Is Essential for the Interactions of SH2-containing Signal Transduction Molecules. *The Journal of Biological Chemistry*, 272(2): pp 1389 – 1394.
- Uchida, N., Hanawa, H., Dan, K., Inokuchi, K., dan Shimada, T., 2009. Leukemogenesis of b2a2-type p210 BCR/ABL in a Bone Marrow Transplantation Mouse Model Using a Lentiviral Vector. *J Nippon Med Sch*, 76(3): pp 134 – 147.
- WHO 2015: Chronic Myeloid Leukemia Staging.
<http://emedicine.medscape.com/article/2006731-overview>. Diakses pada 2 Oktober 2016.